Paper772446
Nalidixic acid and bacterial chromosome replication.
Crumplin GC and 1 other. Nature, 1976. Cited by 65 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Nalidixic acid and bacterial chromosome replication. Papers, record 772446. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/772446
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Chromosomes, Bacterial | Major topic |
| DNA Replication | Major topic |
| DNA, Bacterial | Major topic |
| Nalidixic Acid | Major topic |
| Escherichia coli | |
| Molecular Weight | |
| Mutation | |
| Time Factors |
Source PubMed
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39,598,446 | Antibacterial Mechanisms and Clinical Impact of Sitafloxacin. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39598446 | PubMed |
| 34,199,768 | Mutations in bdcA and valS Correlate with Quinolone Resistance in Wastewater Escherichia coli. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34199768 | PubMed |
| 26,545,354 | Synthesis, characterization, DNA interactions, DNA cleavage, radical scavenging activity, antibacterial, anti-proliferative and docking studies of new transition metal complexes. | J Fluoresc | 2016 | https://conductscience.org/library/papers/26545354 | PubMed |
| 10,747,156 | Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing. | J Clin Microbiol | 2000 | https://conductscience.org/library/papers/10747156 | PubMed |
| 10,553,697 | The future of the quinolones. | Drugs | 1999 | https://conductscience.org/library/papers/10553697 | PubMed |
| 7,689,439 | The future of the quinolones. | Drugs | 1993 | https://conductscience.org/library/papers/7689439 | PubMed |
| 6,347,618 | Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections. | Drugs | 1983 | https://conductscience.org/library/papers/6347618 | PubMed |
| 6,302,690 | recF-dependent induction of recA synthesis by coumermycin, a specific inhibitor of the B subunit of DNA gyrase. | Proc Natl Acad Sci U S A | 1983 | https://conductscience.org/library/papers/6302690 | PubMed |
| 6,271,730 | New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity. | J Bacteriol | 1981 | https://conductscience.org/library/papers/6271730 | PubMed |
| 3,549,037 | Antibacterial therapy in patients with malignancies. | Cancer Metastasis Rev | 1987 | https://conductscience.org/library/papers/3549037 | PubMed |
| 3,438,148 | In vitro activity and mode of action of fluoroquinolones. | Pharm Weekbl Sci | 1987 | https://conductscience.org/library/papers/3438148 | PubMed |
| 3,053,126 | Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use. | Drugs | 1988 | https://conductscience.org/library/papers/3053126 | PubMed |
| 2,971,603 | Single dose oral norfloxacin or intramuscular spectinomycin to treat gonorrhoea (PPNG and non-PPNG infections): analysis of efficacy and patient preference. | Genitourin Med | 1988 | https://conductscience.org/library/papers/2971603 | PubMed |
| 2,665,642 | Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2665642 | PubMed |
| 2,420,724 | [Mechanism of action of quinolones]. | Infection | 1986 | https://conductscience.org/library/papers/2420724 | PubMed |
| 1,963,289 | Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents. | Antimicrob Agents Chemother | 1990 | https://conductscience.org/library/papers/1963289 | PubMed |
| 1,708,224 | Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli. | Antimicrob Agents Chemother | 1990 | https://conductscience.org/library/papers/1708224 | PubMed |
| 375,000 | Mechanisms of recombination by the RecBC and the RecF pathways following conjugation in Escherichia coli K12. | Mol Gen Genet | 1979 | https://conductscience.org/library/papers/375000 | PubMed |
| 326,773 | R-plasmid transfer and its response to nalidixic acid. | J Bacteriol | 1977 | https://conductscience.org/library/papers/326773 | PubMed |
| 321,429 | Temporal sequence of events during the initiation process in Escherichia coli deoxyribonucleic acid replication: roles of the dnaA and dnaC gene products and ribonucleic acid polymerase. | J Bacteriol | 1977 | https://conductscience.org/library/papers/321429 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/772446
GET https://conductscience.org/api/papers/v1/772446/cited_by?page=2